Apellis Pharmaceuticals, Inc.
$40.94
▲
0.05%
2026-04-21 05:20:01
apellis.com
NMS: APLS
Explore Apellis Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.23 B
Current Price
$40.94
52W High / Low
$40.95 / $16.1
Stock P/E
233.76
Book Value
$2.92
Dividend Yield
—
ROCE
7.37%
ROE
7.48%
Face Value
—
EPS
$0.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
733
Beta
-0.2
Debt / Equity
128.15
Current Ratio
3.14
Quick Ratio
2.7
Forward P/E
-167
Price / Sales
5.2
Enterprise Value
$5.22 B
EV / EBITDA
91.62
EV / Revenue
5.2
Rating
Hold
Target Price
$39.93
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 2. | GRI Bio, Inc. | $2.51 | — | $3.68 M | — | -198.85% | -2.38% | $80.36 / $2.1 | $12.07 |
| 3. | Arcturus Therapeutics Holdings Inc. | $8.9 | — | $251.54 M | — | -32.48% | -28.92% | $24.17 / $5.85 | $7.53 |
| 4. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 5. | Cellectar Biosciences, Inc. | $2.95 | — | $12.21 M | — | -224.66% | -1.7% | $20.7 / $2.43 | $1.89 |
| 6. | Omeros Corporation | $13.47 | — | $997.87 M | — | -49.6% | 2.21% | $17.65 / $2.95 | $-1.69 |
| 7. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 199.91 M | 458.58 M | 178.49 M | 166.8 M | 212.53 M | — |
| Operating Profit | -51.14 M | 223.18 M | -33.29 M | -83.33 M | -26.16 M | — |
| Net Profit | -58.95 M | 215.72 M | -42.15 M | -92.22 M | -36.35 M | — |
| EPS in Rs | -0.46 | 1.69 | -0.33 | -0.72 | -0.28 | -0.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1 B | 781.37 M | 396.59 M | 75.42 M |
| Operating Profit | 55.43 M | -164.98 M | -517.12 M | -594.61 M |
| Net Profit | 22.39 M | -197.88 M | -528.63 M | -652.17 M |
| EPS in Rs | 0.18 | -1.55 | -4.14 | -5.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.08 B | 885.05 M | 788.73 M | 760.22 M |
| Total Liabilities | 705.11 M | 656.51 M | 594.21 M | 590.35 M |
| Equity | 370.15 M | 228.54 M | 194.52 M | 169.87 M |
| Current Assets | 1.01 B | 788.95 M | 766.33 M | 719.52 M |
| Current Liabilities | 323.6 M | 185.51 M | 247.59 M | 167.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 45.33 M | -87.87 M | -594.74 M | -513.75 M |
| Investing CF | -0.31 M | -0.4 M | -0.67 M | 59.89 M |
| Financing CF | 8.88 M | 149.24 M | 394.5 M | 365.66 M |
| Free CF | 45.01 M | -88.27 M | -595.51 M | -515.27 M |
| Capex | -0.31 M | -0.4 M | -0.77 M | -1.52 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 97.02% | 425.83% | — | — |
| Earnings Growth % | 62.57% | 18.94% | — | — |
| Profit Margin % | -25.32% | -133.29% | -864.7% | — |
| Operating Margin % | -21.11% | -130.39% | -788.38% | — |
| Gross Margin % | 84.93% | 85.25% | 92.53% | — |
| EBITDA Margin % | -19.78% | -124.85% | -818.49% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.